WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2017059178) HUMAN PLASMA KALLIKREIN INHIBITORS
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2017/059178    International Application No.:    PCT/US2016/054619
Publication Date: 06.04.2017 International Filing Date: 30.09.2016
IPC:
A61K 31/519 (2006.01), C07D 405/12 (2006.01), A61K 31/4439 (2006.01)
Applicants: BIOCRYST PHARMACEUTICALS, INC. [US/US]; 4505 Emperor Boulevard Durham, NC 27703 (US)
Inventors: KOTIAN, Pravin, L.; (US).
BABU, Yarlagadda, S.; (US).
KUMAR, V., Satish; (US).
ZHANG, Weihe; (US).
VOGETI, Lakshminarayana; (US)
Agent: GORDON, Dana, M.; (US).
CHOI, Philip, S.; (US).
BLOUNT, Jennifer, V.; (US).
ABELLEIRA, Susan, M.; (US).
AKHIEZER, Alexander; (US)
Priority Data:
62/235,754 01.10.2015 US
Title (EN) HUMAN PLASMA KALLIKREIN INHIBITORS
(FR) INHIBITEURS DE LA KALLICRÉINE PLASMATIQUE HUMAINE
Abstract: front page image
(EN)Disclosed are compounds of formula I, and pharmaceutically acceptable salts thereof. The compounds are inhibitors of plasma kallikrein. Also provided are pharmaceutical compositions comprising at least one compound of the invention, and methods involving use of the compounds and compositions of the invention in the treatment and prevention of diseases and conditions characterized by unwanted plasma kallikrein activity.
(FR)L'invention concerne des composés de la formule (I), et leurs sels pharmaceutiquement acceptables. Les composés sont des inhibiteurs de la kallicréine plasmatique. L'invention concerne également des compositions pharmaceutiques comprenant au moins un composé selon l'invention, et des méthodes impliquant l'utilisation des composés et des compositions selon l'invention pour le traitement et la prévention de maladies et de pathologies caractérisées par une activité indésirable de la kallicréine plasmatique.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)